A Phase 1 interventional study of Treatment A: JW0106 1 tablet + C2101 1 tablet and Treatment B: JW0107 1 tablet in Healthy, sponsored by JW Pharmaceutical. Completed at 1 site in Korea, Republic of. Open to participants aged 19 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-02-10.
Sponsored by JW Pharmaceutical · Phase 1, Interventional, and Other
The objective is to evaluate the safety and pharmacokinetic characteristics after co-administration of JW0106 and C2101 and administration of JW0107 in healthy volunteers under fasting conditions.
Pharmacokinetic characteristics: Describes the blood concentration statistically by pharmacokinetic blood collection time and treatment group.
Safety: All adverse events are summarized in terms of the number of subjects, expression rate, and number of expressions of adverse reactions by treatment group.
JW Pharmaceutical is the lead sponsor of 75 studies on the registry; 6 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Healthy volunteers
Exclusion Criteria:
Subjects does not meet the inclusion Criteria
(Period 1/3: Treatment A) (Period 2/4: Treatment B) Treatment A: JW0106 1 tablet + C2101 1 tablet Treatment B: JW0107 1 tablet
Drug: Treatment A: JW0106 1 tablet + C2101 1 tablet · Drug: Treatment B: JW0107 1 tablet
(Period 1/3: Treatment B) (Period 2/4: Treatment A) Treatment A: JW0106 1 tablet + C2101 1 tablet Treatment B: JW0107 1 tablet
Drug: Treatment A: JW0106 1 tablet + C2101 1 tablet · Drug: Treatment B: JW0107 1 tablet
* Co-administration of 1 tablet of JW0106 and 1 tablet of C2101 * Administration orally with 150 mL of water under fasting conditions
* Administration alone of 1 tablet of JW0107 * Administration orally with 150 mL of water under fasting conditions
Also known as: Administration alone of 1 tablet of JW0107
AUCt
Describes the blood concentration statistically by pharmacokinetic blood collection time and treatment group.
Time frame: Day 1(0 hour~12 hour), Day 2(24 hour), Day 3(48 hour), Day 4(72 hour)
Cmax
Describes the blood concentration statistically by pharmacokinetic blood
Time frame: Day 1(0 hour~12 hour), Day 2(24 hour), Day 3(48 hour), Day 4(72 hour)
This study is completed, as verified in Feb 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
JW Pharmaceutical